English PrEP Study To Use Mylan’s Generic Version Of Gilead’s Truvada

A study of tenofovir plus emtricitabine in HIV pre-exposure prophylaxis is to begin in England in September, using Mylan’s generic version of Gilead’s originator drug Truvada. Wales is running a similar trial with Truvada, while Scotland has decided to fund the drug for PrEP under the National Health Service.

HIV virus
England is to run a trial of PrEP in HIV prevention

NHS England has announced that the three-year PrEP IMPACT trial testing the efficacy of a combination of tenofovir and emtricitabine in pre-exposure HIV prophylaxis will start enrolment from early September, with full roll-out in English clinical centers expected by April 2018 at the latest.

The £10m PrEP IMPACT trial, described as “the largest single study of its type in the world,” will use Mylan’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D